Published
July 14, 2026
Updated
July 15, 2026
If you filled Pfizer-brand Chantix before the 2021 recall, this is the class action over the nitrosamine impurity that pulled every lot off U.S. shelves — and the consumer/TPP economic-loss claims have now settled for $44 million, with claims open through September 14, 2026.
Allegations Only · No Settlement Yet
This article describes consolidated class action complaints. The statements below are unproven allegations, and Pfizer has not been found liable. The consumer and third-party-payor economic-loss claims have since settled for $44 million (preliminarily approved June 1, 2026, Pfizer denying wrongdoing); see the settlement section below to claim. This page is informational and is not legal or medical advice — do not stop a prescribed medication because of a lawsuit.
What Is This About?
Pfizer's stop-smoking drug Chantix (varenicline) is at the center of consolidated federal litigation over a manufacturing impurity. The cases are gathered as In re: Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II), MDL No. 3050, before Judge Katherine Polk Failla in the U.S. District Court for the Southern District of New York, where Pfizer is headquartered. The Judicial Panel on Multidistrict Litigation consolidated the cases on December 22, 2022.The dispute traces back to Pfizer's 2021 recall of Chantix after tablets were found to contain N-nitroso-varenicline, a nitrosamine impurity, above the company's acceptable intake limit. Plaintiffs allege they paid for — and in many cases took — a product they say was contaminated and should not have been sold. Pfizer has not been found liable, and the allegations remain unproven.
Status
MDL Consolidated — In Litigation
MDL No. 3050 · S.D.N.Y. · Judge Katherine Polk Failla · consolidated Dec. 22, 2022 · ~17 actions pending
The Recall
All U.S. lots recalled (2021)
N-nitroso-varenicline nitrosamine impurity · recalled July → Aug → all lots by Sept. 2021 · product distributed ~2019–2021
Can I Claim?
Yes — $44M settlement, claims open
Consumer & TPP economic-loss claims settled for $44M · file by Sept. 14, 2026 · see the settlement page
Why Pfizer Recalled Chantix
Chantix (varenicline) is a prescription medicine that helps adults stop smoking. In 2021 Pfizer began a voluntary recall after testing found N-nitroso-varenicline — a nitrosamine — in the tablets above Pfizer's acceptable daily intake limit. Nitrosamines are a class of compounds found in trace amounts in water and many foods, and N-nitroso-varenicline is treated as a probable human carcinogen at exposures above acceptable limits over long periods.The recall expanded in stages: it began with a group of lots in July 2021, added more lots in August 2021, and by September 2021 covered all lots of Chantix in the United States. The recalled product had been distributed nationwide roughly between 2019 and 2021. The U.S. Food and Drug Administration's public position was that the benefits of quitting smoking outweighed the theoretical cancer risk from the impurity, and it advised patients not to stop taking varenicline without first talking to their clinician. Generic varenicline from other manufacturers later filled the market; the issue was the manufacturing impurity, not the varenicline molecule itself.
What the Lawsuits Allege
The consolidated complaints allege that the recalled Chantix was adulterated and misbranded because it contained the N-nitroso-varenicline impurity, that it was not manufactured in compliance with current Good Manufacturing Practices (cGMPs), and that Pfizer knew or should have known about the contamination. Plaintiffs bring negligence, consumer-fraud, and related state and common-law claims, and they seek economic damages — essentially the money paid for a product they say was worthless or defective — along with medical monitoring.The litigation is not standing still. In a split ruling in 2024, the court dismissed some of the claims on federal-preemption grounds while allowing others — including claims tied to the alleged cGMP violations — to move forward. As with any complaint, these are allegations only. Pfizer has not been found liable, no class has been certified, and the company disputes the claims.
Is This the "Chantix Cancer" Lawsuit?
Not exactly, and the distinction matters. The consolidated MDL 3050 claims are primarily economic-loss and medical-monitoring claims: plaintiffs say they paid for a recalled, allegedly contaminated product and want refunds and monitoring — not damages for a specific diagnosed cancer. Some plaintiff-side firms advertise "Chantix cancer" claims, but the case as consolidated is built around the consumer-protection and economic-loss theory rather than personal-injury cancer damages.Two other points prevent confusion. First, this nitrosamine litigation is separate from the older Chantix cases over alleged neuropsychiatric side effects (mood changes and suicidality), which Pfizer largely resolved in the prior decade — a different track entirely. Second, the impurity here is N-nitroso-varenicline, not NDMA; NDMA is the nitrosamine tied to the Zantac (ranitidine) and valsartan cases, which are unrelated to Chantix.
Is There a Chantix Settlement Yet?
Yes — for the consumer and third-party-payor economic-loss claims. Pfizer has agreed to pay $44,000,000 to resolve the claims that Chantix contained an undisclosed nitrosamine impurity and that Pfizer misrepresented its adherence to current Good Manufacturing Practices. The Court granted preliminary approval on June 1, 2026, and claims are open.Anyone who paid any amount for retail purchases of Pfizer-brand Chantix in the United States and its territories from September 29, 2015 through September 17, 2021 can file for a pro rata share. Consumers self-report their prescriptions and out-of-pocket cost — no receipts or Notice ID are needed to file — and the claim deadline is September 14, 2026, with a Final Approval Hearing set for October 13, 2026. Pfizer denies any wrongdoing. See our full breakdown of the Chantix $44 million settlement for eligibility, payout, and how to claim. Be skeptical of any website other than the official one (ChantixSettlement.com) presenting a "Chantix claim form."
Who Is Affected and What You Can Do
The economic-loss claims are pleaded on behalf of consumers who bought or took recalled Pfizer-brand Chantix (0.5 mg or 1 mg tablets) during roughly the 2019 to 2021 distribution window. Because MDL 3050's defendant is Pfizer and the case centers on branded Chantix, someone who only ever took a generic varenicline is not automatically part of this litigation.• Do not stop a prescribed medication because of a lawsuit — talk to your clinician about your options, including generic varenicline.
• Keep pharmacy records or receipts showing you filled Chantix during the 2019–2021 window.
• There is nothing to file right now; watch for news of a certified class or settlement.
For drug and device cases that are further along, see OCA's mass tort lawsuits hub.
Frequently Asked Questions
Is there a Chantix nitrosamine settlement yet?
Yes, for the consumer and third-party-payor economic-loss claims. Pfizer agreed to pay $44 million (preliminarily approved June 1, 2026) to resolve claims tied to the alleged nitrosamine impurity and cGMP misstatements; Pfizer denies wrongdoing. Anyone who paid for Pfizer-brand Chantix from September 29, 2015 through September 17, 2021 can file a claim by September 14, 2026. See the Chantix $44M settlement page.Why was Chantix recalled?
Pfizer recalled the tablets in 2021 because they contained N-nitroso-varenicline, a nitrosamine impurity, above its acceptable intake limit. The recall grew from a group of lots in July 2021 to all U.S. lots by September 2021.Do I need to file a claim?
To get a payment from the $44 million consumer/TPP settlement, yes — file by September 14, 2026. Consumers self-report their prescriptions and out-of-pocket cost, so no receipts or Notice ID are required to file, though keeping pharmacy records is wise in case the administrator asks.Sources
• Judicial Panel on Multidistrict Litigation — transfer order creating MDL No. 3050 (Dec. 22, 2022): JPML Transfer Order• CourtListener — docket for In re Chantix (Varenicline)…, No. 1:22-md-03050 (S.D.N.Y.): CourtListener Docket
• U.S. Food and Drug Administration — updates on nitrosamine in varenicline (Chantix): FDA Nitrosamine / Varenicline Updates
• U.S. Food and Drug Administration — Pfizer expands the Chantix recall to additional lots: FDA Recall Notice
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
For more class actions keep scrolling below.
Status
MDL Consolidated — In Litigation (no settlement)
Case Title
In re: Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II)
MDL Number
MDL No. 3050 · No. 1:22-md-03050
Court
U.S. District Court, S.D.N.Y. · Judge Katherine Polk Failla
Consolidated
December 22, 2022
Court Docket
CourtListener Docket
